Karuna CEO on going commercial alone

Today's Big News

Jan 10, 2023

Pfizer entering the 'most important' 18-month stretch in company history, CEO says


CVS Health still weighing next steps as it plans foray into primary care


Karuna CEO says biotech can launch drugs too, as deal rumors circulate


'What has the pandemic done for us?' Freenome and other diagnostics developers on making tests more accessible


Fierce Pharma’s JPM Tracker, Day 2: Amgen CEO reflects on pricing law


Fierce Biotech’s JPM Tracker, Day 2: VCs still interested in sector


Fierce Healthcare’s JPM Tracker, Day 2: Aetna expects to add 700K exchange members

 

Featured

JPM23: Pfizer entering the 'most important' 18-month stretch in company history, CEO says

Pfizer was among the drugmakers most elevated by the COVID-19 pandemic, and, going forward, the pharma giant has no plans to give up on its current momentum. 
 

Top Stories

JPM23: CVS Health still weighing next steps as it plans foray into primary care

SAN FRANCISCO—The top brass at CVS Health reiterated Tuesday that the healthcare giant is still plotting its move into primary care but emphasized that they want to ensure the next steps are the right ones.

JPM23: Karuna CEO says biotech can launch drugs, too, as deal rumors circulate

Karuna Therapeutics is 24 months out from a hotly anticipated schizophrenia drug launch and the industry is buzzing with rumors that the biotech will seek a Big Pharma partnership or other deal for commercialization.

JPM23: 'What has the pandemic done for us?' Freenome and other diagnostics developers on making tests more accessible

In interviews with Fierce Medtech during the annual J.P. Morgan Healthcare Conference on Monday, leaders from Freenome, Babson Diagnostics and Immunexpress discussed their ongoing plans to make a wide range of blood tests as broadly accessible and as simple to use as possible.

JPM23: New Biogen CEO Viehbacher aims to steer away from 'melting iceberg' and redefine the company

Biogen's new CEO, Chris Vienbacher, has a lot of mess to clean up. Instead of pushing towards big M&A, which many expected of him due to his background at the helm of Sanofi, he has in-house work to do first as he aims to do some "redefinition" of the company.

JPM23: Teladoc revises its Q4 to sunnier projections while shining a light on BetterHelp and digital 'whole-person approach'

Teladoc CEO Jason Gorevic used the telehealth company's Monday presentation at the J.P. Morgan Healthcare Conference to emphasize a steady march to telehealth permanence within healthcare.

JPM23: With new production lines, ResMed aims to meet CPAP machine demand amid Philips' ongoing recall

Investments in international manufacturing facilities and component contracts are setting ResMed up to better meet patient needs in 2023 and beyond.

JPM23: Sage CEO says postpartum depression is no niche, as zuranolone aims to fill gaps in mental healthcare

Sage Therapeutics is trying to pick up pieces of the depression market that have long been left behind, including patients who are not fully served by existing meds and postpartum mothers who have never had an easy, fast option to try.

AbbVie's Rinvoq ends the year on a high as it tops the TV drug ad spending list for December

AbbVie’s Rinvoq took December’s TV drug ad spend crown, and its fierce rival in Sanofi and Regeneron’s Dupixent was in second place as both replicated their November positions but spent less than the month before.

JPM23: Carbon Health nabs $100M, CVS Health partnership to pilot primary care in retail stores

Startup Carbon Health is partnering with CVS Health to pilot its primary and urgent care services in the drugstore giant's retail stores. CVS' corporate venture arm also led a $100 million investment to accelerate Carbon Health's expansion into new markets.

JPM23: As restructuring continues and revenues grow, Invitae CEO warns total recovery won't happen this year

In an interview with Fierce Medtech at the J.P. Morgan Healthcare Conference, Invitae CEO Kenneth Knight discussed how the nearly two decades he spent at General Motors, Caterpillar and Amazon prepared him to lead a genetic testing company.

JPM23, Day 2: Amgen CEO reflects on pricing law; GSK eyes vaccine showdown with Pfizer

On the second day of the J.P. Morgan Healthcare Conference, GSK, Bayer, Roche and many others are set to share updates about their operations.

JPM23, Day 2: VCs still interested in sector, Karuna wants to go it alone

All you need to know from the second day of the J.P. Morgan Healthcare Conference.

JPM23, Day 2: Walgreens CEO talks Summit Health deal; Aetna expects to add 700K exchange members

All the latest healthcare and health tech news from the J.P. Morgan Healthcare Conference in San Francisco.
 
Fierce podcasts

Don't miss an episode

'The Top Line': 2022's rotten tomatoes, plus this week's headlines

This week on “The Top Line,” we discuss the biotech industry’s rotten tomatoes. Plus, we cover the drug approvals of last year, a congressional report on Biogen's "inappropriate" communications with the FDA and other top headlines from this week.
 

Resources

Whitepaper

Medical Affairs Metamorphosis V: The (R)evolution in Medical Communications

This paper explores how Medical Affairs is adapting medical communications to meet the demands of a new environment (part 5 in a series).
On-Demand Webinar

Writing the Future of Antibody Discovery Solutions

See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions.

Executive Summary

Scale-Up Strategies for Late-Stage Cell Therapies

Readers will learn manufacturing by Design Builds on Quality by Design, De-risking the Tech Transfer Process, and more.

Whitepaper

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?
Whitepaper

Linear Compression vs. Parallel Processing: Speeding Biologics Through Development and Into Clinical Trials

Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more.

Whitepaper

Intranasal Drug Product Development: Formulation to Manufacturing

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?
Whitepaper

Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.
Case Study

A Strategy to Standardize Process Characterization & Late Phase Development

Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments.

Whitepaper

Clinical Supply Solutions for the Asia-Pacific Region

Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region.
Whitepaper

Supply Services to Support Clinical Trials in Japan & Beyond

Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world.
 

Industry Events

 

Upcoming Fierce Events

10
Jan
San Francisco, CA
17-19
Jan
Virtual Event
27-28
Feb
Arlington, VA
14-15
Mar
San Francisco, CA
20-22
Mar
West Palm Beach, FL

View all events